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Neoplastic cell percentage estimation in tissue samples for molecular oncology: recom-
mendations from a modified Delphi study
Aims: Results from external quality assessment
revealed considerable variation in neoplastic cell per-
centages (NCP) estimation in samples for biomarker
testing. As molecular biology tests require a minimal
NCP, overestimations may lead to false negative test
results. We aimed to develop recommendations to
improve the NCP determination in a prototypical
entity – colorectal carcinoma – that can be adapted
for other cancer types.
Methods and results: A modified Delphi study was
conducted to reach consensus by 10 pathologists
from 10 countries with experience in determining the
NCP for colorectal adenocarcinoma. This study
included two online surveys and a decision-making
meeting. Consensus was defined a priori as an agree-
ment of > 80%. All pathologists completed both
surveys. Consensus was reached for 8 out of 19 and
2 out of 13 questions in the first and second surveys,
respectively. Remaining issues were resolved during
the meeting. Twenty-four recommendations were for-
mulated. Major recommendations resulted as follows:
only pathologists should conduct the morphological
evaluation; nevertheless molecular biologists/techni-
cians may estimate the NCP, if specific training has
been performed and a pathologist is available for feed-
back. The estimation should be determined in the
area with the highest density of viable neoplastic cells
and lowest density of inflammatory cells. Other rec-
ommendations concerned: the determination protocol
itself, needs for micro- and macro-dissection, report-
ing and interpreting, referral practices and applicabil-
ity to other cancer types.
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Conclusion: We believe these recommendations may
lead to more accurate NCP estimates, ensuring the
correct interpretation of test results, and might help
in validating digital algorithms in the future.
Keywords: molecular biomarker testing, neoplastic cell percentage, recommendations
Introduction
Molecular analysis of solid tumours has become stan-
dard practice for many cancer types. Because the out-
come of those tests has a significant impact on
deciding which systemic therapy is used in the indi-
vidual patient, the testing process must be as precise
and reliable as possible.1,2 Much has been written
about avoiding errors related to certain test method-
ologies.3–6 Before tumour DNA is analysed, the most
suitable tissue block must be selected. Important
aspects of the pre-analytical process include identifica-
tion of the tumour area, determination of the neo-
plastic cell percentage (NCP) within that area,
verification of the representativeness of the sample
and, finally, the diagnosis, especially in situations
when the tumour tested represents a metastasis. As
testing strategies require a minimal amount of neo-
plastic cells in the samples tested for a reliable molec-
ular test result (a parameter which directly influences
the sensitivity of the test), it is important to select a
sample that contains a sufficient number and/or per-
centage of neoplastic cells.7 Most molecular testing
techniques require at least 5–10 ng DNA for a reli-
able analysis, which generally correspond to a mini-
mum of 850–1700 cells.8,9 Test failures in routine
testing or during clinical trials have indeed been
reported due to an insufficient NCP.10–13 The NCP is
also key for correct interpretation of the test outcome.
Testing samples with insufficient NCPs might lead to
false negative results, as it is uncertain whether the
sample truly does not contain a variant or whether
there was an insufficient number of neoplastic cells.
When next-generation sequencing (NGS) is used, an
accurate NCP determination is essential to distinguish
signals from noise, as the variant allelic frequency
(VAF) can only be interpreted in the context of the
NCP.14 In this scenario, if the NCP is overestimated,
it might also be mistakenly thought that a tumour
subclone is present. NCPs also have an impact on the
interpretation of NGS quality metrics, as samples with
low NPCs require higher coverages.5,15 In addition,
correct NCP estimation aids in distinguishing somatic
from germline variants, with implications for the
management of the patient and their relatives.
Several studies have already shown significant vari-
ation in NCP estimates; on average, as high as 20%
between different pathologists.16–18 This was recently
confirmed by a large European-wide study, which
also identified large differences in the processes
related to the estimation of the NCP, such as contour-
ing the tumour area and macrodissection.19 In addi-
tion, this study identified problems with interpreting
the NCP. Here we address these issues and provide
consensus-based recommendations for the determina-
tion of the NCP and related processes as a first step to
decrease interobserver variation and to increase the
awareness of the importance of correct NCP
determination.
Methods
To obtain consensus-based recommendations, a modi-
fied version of the Delphi method was used.20 The
study consisted of two surveys and two conferences.
This study was conducted for colorectal adenocarci-
noma in view of the high frequency and importance
of molecular biomarker testing in this cancer type.
E X P E R T S E L E C T I O N
To assure credibility with the target audience, 10
experienced pathologists from 10 different countries
(Austria, Belgium, Czech Republic, Denmark, Finland,
France, Germany, Italy, the Netherlands and United
Kingdom) were selected to participate based on previ-
ous experience in molecular pathology, relevant pub-
lications and collaborations.
D E L P H I R O U N D S
For the first survey, statements regarding the determi-
nation of the neoplastic cell content were drafted
based on literature review and a survey that was pre-
viously conducted as part of an external quality
assessment scheme for colorectal cancer, as described
elsewhere.19 The expert panel was asked to indicate
the extent to which they agree with the statements
and to explain their choice. Consensus was defined a
priori as an agreement of > 80% between the experts.
Statements for which no consensus was reached were
formulated again in the second survey, together with
an overview of the different views. Furthermore, the
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experts were given the opportunity to include addi-
tional statements during the first survey.
In round 3, the experts met personally for a 2-day
meeting aimed at achieving a final consensus. Each
statement was discussed with a focus on those for
which no consensus had been reached. After a short
discussion, a final vote was held. Afterwards, the
newly proposed protocol for the selection of the area
in which the NCP should be determined and the esti-
mation itself were tested in practice using a multi-
head microscope on 25 haematoxylin and eosin
(H&E)-stained slides from formalin-fixed paraffin-em-
bedded (FFPE) resection specimens from colorectal
adenocarcinoma.
After the meeting, the revised consensus statements
were distributed to the experts present at the meeting
to obtain their agreement on the exact wording of
the statements. Subsequently, the statements were
forwarded to the pathologists who had not been pre-
sent at the onsite meeting. Final consensus was
obtained afterwards during a teleconference.
Results
All invited pathologists agreed to participate as
experts in this Delphi study, except for one patholo-
gist who suggested a colleague with comparable expe-
rience. The experts had, on average, 12 years of
experience in molecular pathology with a routine
evaluation of at least 10 slides per week during their
diagnostic practice.
The first survey contained 19 statements subdi-
vided into the categories described below. Two state-
ments were considered improperly worded, and
consensus was reached on eight statements. The sec-
ond survey included the 11 remaining statements for
which no consensus had been originally reached,
including the different opinions and two additional
statements that had emerged from expert feedback.
During the consensus meeting 24 recommendations
regarding the determination of the NCP were formu-
lated and categorised (Table 1).
Figure 1 shows examples of elements that should
be avoided, such as infiltrating inflammatory cells,
desmoplastic stroma, necrosis and mucus. Among
inflammatory cells, only lymphocytes are easily visi-
ble on routine H&E stains, whereas macrophages
can be quite easily underestimated. Finally, the
experts want to stress that they prefer the term
‘neoplastic cells’ over ‘tumour cells’, as the tumour
might also contain other cell types such as inflam-
matory cells.
Discussion
Estimation of the NCP is regarded as a trivial step
performed very quickly and routinely, yet each
pathologist performs this differently and data pub-
lished so far indicate that it is time to work on stan-
dardisation of this particular procedure. Accurate
estimation is extremely important to correctly inter-
pret the results of a molecular analysis which, in
turn, is crucial for treatment decision-making. Inac-
curate estimations may impact upon patient out-
comes.19 The present study proposes
recommendations for standardising the processes
related to defining the tumour area for macrodissec-
tion and for estimating the neoplastic cell percentage
within this area.
As a previous study has already indicated, in most
laboratories the pathologist determines the NCP.19
The expansion of available biomarkers has increased
the workload of pathologists, and therefore the
experts believe that the NCP could be estimated by
molecular biologists or technicians, provided they are
properly trained, and only after the tissue slide has
been morphologically examined by the pathologist to
confirm entity typing. ‘Proper training’ is defined by
the experts as recognised training in molecular
pathology organised by a national society. As this
type of training is not available in most countries, an
extensive internal training programme could be pro-
vided by the laboratory, as required by ISO
15189:2012 and by Cree et al.21,22 The internal
training must be properly supervised, followed by
competence assessment and regular updates to main-
tain competency. Pathologists, as well as molecular
biologists and technicians, could also consider attend-
ing external training sessions and benchmark them-
selves by comparing their estimates with colleagues
or online training sets, if available. As the NCP is key
to the accuracy of the downstream molecular analy-
ses, experts believe that, on one hand, properly
trained molecular biologists or technicians can assess
this feature, and on the other hand a pathologist
should always be available to double-check and
supervise the process, especially whenever unusual
findings and/or difficult cases are encountered.
The estimation of the NCP should be performed
grossly as the percentage neoplastic cells versus all
cells in a zone for dissection. By ‘grossly’, we mean in
contrast to counting individual cells or to counting
individual cells in a limited area followed by multiply-
ing this number for the total area. It is also important
that the percentage of nuclei is estimated, and not
the area the respective cells are covering. Large
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Table 1. Consensus-based recommendations related to estimating the neoplastic cell percentage before molecular analysis
Part 1: General statements
1. The neoplastic cell percentages (NCP) should be determined in daily practice
2. Every case must be evaluated (morphological evaluation and diagnosis) by a pathologist before a molecular test is
performed
3. The estimation of the NCP should be performed by the pathologist evaluating the case, but may also be
performed by a molecular biologist/technician who attended a training programme that is officially recognised
by a national society,
if available, and who has access to a pathologist for double checking, especially whenever encountering any
unusual findings or difficult cases
Note After molecular analysis, the haematoxylin and eosin (H&E) (on which the initial diagnosis was made)
should be available for the pathologist who signs the molecular report
Part 2: Determination protocol
4. Manually counting individual cells is not suitable in daily practice
5. The estimation should be made as accurately as possible in deciles
Note 1: It is not sufficient to state ‘below or above the threshold’
Note 2: Categories might also be used as long as they are thoroughly validated and tuned between the different
pathologists of one pathology department
Note 3: Cases with NCPs close to the threshold should be discussed with the molecular biologist
6. Gross estimation: percentage neoplastic cells versus all cells in a zone for dissection is most suitable
7. Selection of the area for neoplastic cell content estimation: select the area with the highest density of viable neoplastic cells
and the lowest density of inflammatory cells. Avoid areas of necrosis and mucus (Figure 1).
It is better to have a smaller area with fewer non-neoplastic cells than a larger area with many
non-neoplastic cells
8. All non-neoplastic nuclei (such as inflammatory cells, desmoplastic stroma and fat tissue) should be taken into
account when estimating the neoplastic cell count
9. All areas without nuclei (such as mucus and necrosis) can be visual confounders
10. The tumour area can be marked by gross methods (such as gross circles and gross tumour shape), because this fits best with
macrodissection
Note: If there are only small areas with high neoplastic cell counts (for example,
because of necrosis) or heterogeneous samples, indication by one or more small circles is also possible
11. Suggested protocol for a surgical specimen (Figures 2 and 3):
• Select the most cellular area of the tumour (avoid artefacts) under low magnification
• Check at high magnification whether the area is homogeneous (inflammatory cell
infiltrates, areas of necrosis, etc.)
• Contour the tumour area:
○ Homogeneous samples: Estimate the NCP at intermediate magnification as the percentage
of neoplastic cells versus all cells in the area that will be used for macrodissection
○ Heterogeneous samples: Estimate multiple areas under intermediate magnification and
take the average valueNote: for endoscopic biopsies a high magnification should be used
• Take notes:
○ NCP
○ Conclusion: is the sample suitable or not for molecular downstream analyses?
13. An H&E-stained section cut after the molecular analysis may be analysed if required in the process, especially in
endoscopic or image-guided biopsies
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neoplastic cells are visually more outstanding than
smaller lymphocytes, yet the amount of DNA in both
cell types is comparable. It is recommended to make
the estimation in deciles (e.g. 20%) or in categories
which still enable correlation of the NCP with the
variant allelic frequency (VAF) of the specified vari-
ant.14 For example, when a VAF is higher than
expected, the variant might be a germline, or the
gene might be affected by heterozygosity or tumour
cell aneuploidy might have occurred. Conversely, if a
low VAF is detected in a sample with a high NCP,
the result could be interpreted as a testing artefact or
as an indicator for subclonality of a given gene in the
context of tumour heterogeneity. In these scenarios,
testing an alternative tumour sample is good practice
and helps to rule out artefacts. If categories are used,
they should be thoroughly validated as part of the
whole testing procedure and tuned between individ-
ual observers. Examples of categories are < 10, 10–
30, 30–50, 50–90 and> 90%. Regardless of how the
NCP is reported, it is critical to know the threshold
(minimum required NCP) and sensitivity of the test-
ing method. Estimates around this cut-off should be
made with extra care and discussed with the molecu-
lar laboratory where, when interpreting the quality
metrics of the testing method, these can be acted
upon.
When selecting the area with the highest density of
viable neoplastic cells, areas with inflammatory cells,
necrosis, desmoplastic stroma and mucus, as depicted
in Figure 1, should be avoided, as those areas contain
viable nuclei diluting the amount of neoplastic DNA.
Although the study by B€uttner et al. indicates that
avoiding necrosis and mucus on colorectal specimen
has no impact on the test outcome, others have set
the acceptable amount of necrosis at 20% in various
cancer types.23–25 It should be added that, when con-
touring the selected tumour area for macrodissection,
a pen with an appropriate thickness should be used.
Macrodissection is always recommended, unless the
sample contains a sufficient number (both absolute
and relative) of viable neoplastic cells. Special
Table 1. (Continued)
Part 3: Need for micro- and macrodissection
14. Dissection should be performed in most cases, unless the whole section contains a sufficient NCP
15. Macrodissection is generally sufficient, but depending on the sample a magnifier can be usedNote: Macrodissection
means ‘without the use of a microscope’
16. Laser-guided microdissection is not recommended for daily routine practice
17. It is recommended to perform the dissection on unstained slides
18. Whether the marked area corresponds to the macrodissected area in the process of macrodissection
should be checked
Part 4: Reporting and interpretation
19. The NCP should be included in the report
20. The NCP should be taken into account for interpretation of the test result
21. The following warning note should be added when no mutation is identified and the NCP is below the threshold
of the molecular technique:
‘Due to a low NCP, a false negative result cannot be excluded. If possible and clinically
relevant, a specimen with higher NCP should be tested’
22. The following warning note should be added for positive results when the NCP is below the threshold of the molecular
technique, where appropriate: ‘Due to low neoplastic cell content, a false negative result for other tested genes
cannot be excluded. If possible and relevant, a specimen with higher NCP should be tested’
Part 5: Additional items
23. When samples from external laboratories are to be analysed, the pathologist who receives the blocks from
elsewhere and performs the molecular analysis should make the estimation or check if there is agreement with
the original estimate, if any
24. These recommendations are easy to apply and extend to other cancer types
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attention should be paid when handling samples for
molecular analysis to prevent contamination, as
described elsewhere.26 Different methods are available
for macrodissection, but no research has been con-
ducted on their effects on test outcome. For example,
tissue outside the contoured area can be scraped off
using a diamond pen, or the contoured tissue can be
scraped off and collected in a microtube.26–28 To
increase dissection accuracy a magnifier can be used,
but a microscope is not necessary according to the
experts, as this is too time-consuming. Given its high
cost and complexity, laser-guided microdissection is
also not recommended to be used, apart from very
rare cases where small areas or individual cells are
essential to be analysed. With the current rapid devel-
opment in digital pathology applications, other digi-
tally guided dissection systems could enter laboratory
practice during the next decade.29
For correct interpretation of the test result, it is
important for the clinician to understand the test
validity. Therefore, the NCP should be clearly
included in the molecular test report, and the
methodology section of the report should include
test sensitivity and the list of variants that were
included in the analysis. This is not only recom-
mended by experts, but also by several interna-
tional standards and guidelines.21,30–32 When the
NCP is below the threshold of the test method
molecular testing should not be performed at all, or
if the NCP is close to the threshold a disclaimer
should be added to draw the clinician’s attention.33
This is not only recommended when no mutation
is identified in the sample, but also for positive
results in case of multiplex panel testing. Method
sensitivities might differ per gene in the panel, and
a positive result for one gene does not exclude a
false negative result for another gene.
A modified form of the Delphi technique was used
to obtain these consensus-based recommendations.
This technique has some major advantages, such as
the ability to bring together experts from different
countries, the structured communication process and
time-effectiveness. The technique also has a weak-
ness, in that no guidelines exist for determining the
level of consensus and the minimal number of experts
needed.34 Therefore, we decided to set the consensus
level in advance at an agreement of 80%, and we
were of the opinion that the expertise and years of
experience of the panel members is more important
than the number of participants. Although this study
focused on NCP processes for colorectal cancer, the
experts believe that the proposed recommendations
can be applied to other cancer and sample types (e.g.
cytological preparations, including smears and cell
blocks), taking into account the specific morphologi-
cal properties of the tumour. One limitation related to
A B
C D
Figure 1. Examples of elements that should be avoided when contouring the tumour area. Images of haematoxylin and eosin-stained forma-
lin-fixed paraffin-embedded tissue from metastatic colorectal cancer showing examples of elements that should be avoided when contouring
the tumour area. A, Abundant presence of inflammatory cells. B, Extensive presence of desmoplastic stroma. C, Abundant (‘dirty’) necrosis.
D, High-mucinous sample
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cytological samples remains the reduced ability to
macrodissect tumour out of cytological preparation
due to the mixed cellularity often represented in these
samples (‘contaminating’ inflammatory cells,
mesothelial cells) and the somewhat high variation in
cellularity between the levels analysed.
This study resulted in consensus-based recommen-
dations concerning practices related to the visual esti-
mation of the NCP. Although the proposed protocols
might not be adopted in the same way by all labora-
tories, this study also aimed to increase awareness of
the importance of an accurate estimation of the NCP
Low
magnification
Non-neoplastic cell
Neoplastic cell
Necrosis
Mucus
Note:
NCP
Sample suitable
or not
Homogeneous
sample
Areas for
macrodissection:
60% neoplastic
calls on average
Area for
macrodissection:
60% neoplastic
calls
Heterogeneous
sample
Intermediate
magnification
Figure 2. Proposed protocol for the determination of the neoplastic cell content. This figure visually illustrates the proposed protocol for esti-
mating the neoplastic cell percentages (NCP). First, the most cellular area of the tumour has to be selected under low magnification and
artefacts (as exemplified by Figure 1) should be avoided. At high magnification it should then be checked whether or not the area is homo-
geneous. For homogeneous samples the NCP could be estimated at intermediate magnification, as the percentage of neoplastic cells versus
all cells in the area that will be used for macrodissection. In heterogeneous samples, the estimation is the average of estimates made under
intermediate magnification in multiple areas. After determining the percentage neoplastic cells, the NCP should be noted, and also whether
the sample is suitable for downstream analysis or not
A B
C D
Figure 3. Examples of grossly delineated zones for microdissection. Images of haematoxylin and eosin-stained formalin-fixed paraffin-embed-
ded tissue from metastatic colorectal cancer with the gross delineation of the area to be macrodissected. A, Zone with 30% neoplastic cells.
A mucinous zone was eliminated for macrodissection. B, Zone with 40% neoplastic cells, avoiding an area where solitary neoplastic cells are
spread. C, Zone with 50% neoplastic cells. D, Zone with 70% neoplastic cells
© 2019 The Authors. Histopathology Published by John Wiley & Sons Ltd, Histopathology, 75, 312–319.
318 K Dufraing et al.
and its implications for high-quality molecular test-
ing, and eventually to reduce the variation in the
practice of reporting the NCP. The possibilities of digi-
tal estimates also need to be further explored, as sys-
tems are becoming commercially available.
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